Last week at the Cleveland Clinic’s annual Medical Innovations Summit, Daniel Kraft, chair of medicine and neuroscience at Singularity University, and an oncologist, painted a dazzling picture of a healthcare future where digital tools empower everyone and can solve several of healthcare’s bigger problems.
But he also posed a question whose answer will be borne out over the next few years: The tech and data tsunami is coming, but do we have the right platforms in place to catch the wave?
TEDCO is happy to announce its new Seed Investment Fund. After careful consideration of feedback received from our recent market stakeholder survey, we’ve decided to transform our Technology Commercialization Fund (TCF), Cyber Security Investment Fund (CIF) and Life Science Invest,ment Fund (LSIF) into a single Seed Investment Fund.
The new program will make it easier than ever for startup technology companies to seek Seed Funding from TEDCO.
GE Healthcare and Johns Hopkins Hospital partnered to construct a NASA-style command center to better manage patient safety, experience and volume. The Judy Reitz Capacity Command Center leverages systems engineering principles that are commonly used in the aerospace, aviation and power industries.
There are a lot of scientific papers out there. One estimate puts the count at 1.8 million articles published each year, in about 28,000 journals. Who actually reads those papers? According to one 2007 study, not many people: half of academic papers are read only by their authors and journal editors, the study’s authors write.
But not all academics accept that they have an audience of three. There’s a heated dispute around academic readership and citation—enough that there have been studies about reading studies going back for more than two decades.
Vigilant Bioservices Open House In the UMB Biopark 801 W. Baltimore St., Suite 303, Baltimore, Md. 21201 (street parking & garage on same block west of Biopark)
Wednesday, November 16th
(Tours start on the half hour) 11am – 1pm 3pm – 5pm
Join us for the monthly Science in the City Happy Hour With the tenants of the Biopark 5:00pm-6:30pm
RSVP: tokeefe@vigilantbioservices.com
Stephen Quake’s laboratory at Stanford University looks like biology’s version of Thomas Edison’s famous New Jersey workshop. Roll-down curtains cast shadows across odd devices buzzing and clicking in the aisles. You half expect to find Quake, author of 135 patents and rarely seen wearing anything other than a faded polo shirt, sleeping on one of the benches, just as the Wizard of Menlo Park was known to.
The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC).
Immunomic Therapeutics is committed to providing a workplace that bolsters scientific ideas. The Cancer Discovery Incubator will enable and accelerate beginning ventures with the capacity for measurable change in oncology health. The goal is to empower the beneficiary to conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth.
New York biotech has historically lagged behind more established life sciences hubs like Boston and San Francisco, but collaborations between its research institutions have helped the city start to move forward. Another step in that direction was taken this morning, with the launch of what’s being called Bridge Medicines.
Reston-based telemedicine provider Avizia Inc. raised $6 million in Series A funding, amping up a fundraising round we reported earlier this year to a total of $17 million.
